While SphK1 activity can be stimulated by a wide array of growth factors [26], we have previously shown in prostate cancer cell and animal models that anticancer treatments (chemotherapeutic agents or ionizing radiations) lead to its inhibition suggesting that SphK1 could act a sensor to anticancer therapies [35], [36], [37], [38]. The gene discussed is SPHK1; the disease is prostate carcinoma.